Growth Metrics

Marimed (MRMD) Net Income towards Common Stockholders (2016 - 2025)

Marimed (MRMD) has disclosed Net Income towards Common Stockholders for 15 consecutive years, with -$4.6 million as the latest value for Q4 2025.

  • Quarterly Net Income towards Common Stockholders rose 43.84% to -$4.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$14.3 million through Dec 2025, down 17.13% year-over-year, with the annual reading at -$14.5 million for FY2025, 16.3% down from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$4.6 million at Marimed, down from -$2.9 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $7.6 million in Q2 2021, with the low at -$10.1 million in Q4 2023.
  • Average Net Income towards Common Stockholders over 5 years is -$1.1 million, with a median of -$1.1 million recorded in 2024.
  • The sharpest move saw Net Income towards Common Stockholders soared 764.98% in 2021, then crashed 319.5% in 2025.
  • Over 5 years, Net Income towards Common Stockholders stood at -$6.4 million in 2021, then skyrocketed by 174.23% to $4.7 million in 2022, then tumbled by 313.27% to -$10.1 million in 2023, then grew by 18.4% to -$8.3 million in 2024, then surged by 43.84% to -$4.6 million in 2025.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at -$4.6 million, -$2.9 million, and -$1.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.